Abstract
Among the previously studied organic vanadium derivatives showing an anti-diabetic action, we investigated a new complex, bis(2,2′-bipyridine)oxovanadium(IV) sulphate. We tested its ability to normalise parameters previously described for streptozotocin (STZ)-diabetes, such as lower yields of Golgi-rich membrane fraction isolation, decreased activity of Golgi membrane marker enzyme - galactosyltransferase (GalT) - and altered morphology of rat liver Golgi complexes. Oral application as a drinking solution of 1.8 mmol bis(2,2′-bipyridine)oxovanadium(IV) (dissolved in 0.09 M NaCl) caused a similar dispersion of GalT activities in both vanadium treated groups, control and diabetic. Very low activities of the enzyme (characteristic for untreated diabetes) we found only in approximately 35 % of the STZ-diabetic rats treated with the new vanadium compound. The morphology of liver Golgi complexes in diabetic rats treated with bis(2,2′-bipyridine)oxovanadium(IV) sulphate was improved, which manifested itself in the reappearance of vacuoles with VLDL and coated and uncoated secretory vesicles. In view of biochemical and morphological parameters of normalised diabetic rat liver Golgi apparatus, the new vanadium complex was more effective than bis(oxalato)oxovanadium(IV) or bis(kojato)oxovanadium(IV), but in our experimental model, the best anti-diabetic, orally applied drug was the bis(maltolato)oxovanadium(IV) previously investigated.
Key words
Golgi Complexes - Bis(2,2′-bipyridine)oxovanadium(IV) - Galactosyltransferase (GalT) - Pathology - Liver - Streptozotocin (STZ)
References
1
Heyliger C E, Tahiliani A G, McNeill J H.
Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats.
Science.
1985;
227
1474-1477
2
Tsiani E, Fantus I G.
Vanadium compounds. Biological actions and potential as pharmacological agents.
Trends Endocrinol Metab.
1997;
8
51-58
3
Domingo J L.
Vanadium and diabetes. What about vanadium toxicity?.
Mol Cell Biochem.
2000;
203
185 -187
4
Aharon Y, Mevorach M, Shamoon H.
Vanadyl sulfate does not enhance insulin action in patients with type 1 diabetes.
Diabetes Care.
1998;
21
2194-2195
5
Cam M C, Brownsey R W, McNeill J H.
Mechanisms of vanadium action: insulin-mimetic or insulin-enhancing agent.
Can J Physiol Pharmacol.
2000;
78
829-847
6
Goldfine A B, Patti M E, Zuberi L, Goldstein B J, LeBlanc R, Landaker E J, Jiang Z Y, Willsky G R, Kahn C R.
Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies.
Metabolism.
2000;
49
400-410
7
Badmaev V, Prakash S, Majeed M.
Vanadium: a review of its potential role in the fight against diabetes.
J Alternat Complement Med.
1999;
5
273-291
8
Crans D C.
Chemistry and insulin-like properties of vanadium(IV) and vanadium(V) compounds.
J Inorg Biochem.
2000;
80
123-131
9
Fantus I G, Tsiani E.
Multifunctional actions of vanadium compounds on insulin signalling pathways: evidence for preferention enhancement of metabolic vs. mitogenic effects.
Mol Cell Biochem.
1998;
182
109-119
10
Cam M C, Li W M, McNeill J H.
Partial preservation of pancreatic beta cells by vanadium. Evidence for long-term amelioration of diabetes.
Metabolism.
1997;
46
769-778
11
Shafrir E, Spielman S, Nachliel I, Khamaisi M, Bar-On H, Ziv E.
Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil.
Diabetes Metab Res Rev.
2001;
17
55-66
12
Yuen V G, Caravan P, Gelmini L, Glover N, McNeill J H, Setyawati I A, Zhou R, Orvig C.
Glucose lowering properties of vanadium compounds. Comparison of coordination complexes with maltol or kojic acid as ligands.
J Inorg Biochem.
1997;
68
108-116
13
Da˛brosŽ W, Dziga D, GrybosŽ R, Kordowiak A M.
Biochemical and morphological alterations in rat liver Golgi complexes after treatment with bis(maltolato)oxovanadium(IV) [BMOV] or maltol alone.
Path Res Pract.
2000;
196
561-568
14
Da˛brosŽ W, Kordowiak A M, Dziga D, GrybosŽ R.
Influence of bis(maltolato)oxovanadium(IV) on activity of galactosyltransferase (GalT) and morphology of rat liver Golgi apparatus in control and streptozotocin diabetes.
Pol J Pathol.
1998;
49
67-76
15
Kordowiak A M, Nikiforuk A, Da˛brosŽ W.
Biochemical and morphological study of rat liver Golgi complex in streptozotocin-diabetic and control rats treated with bis(kojato)oxovanadium(IV) [VO(ka)2 ] × 2H2 O. Part I. One-week treatment with vanadium compound.
Pol J Pathol.
2000;
1
9-16
16
Woo L CY, Yuen V G, Thompson K H.
Vanadyl-biquanide complexes as potential synergistic insulin mimics.
J Inorg Biochem.
1999;
76
251-257
17
Yuen V G, Orvig C, McNeill J H.
Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
Can J Physiol.
1995;
75
55-64
18
Bhanot S, Girn J, Poucheret P, McNeill J H.
Effects of bis(maltolato)oxovanadium(IV) on protein serine kinases in skeletal muscle of streptozotocin-diabetic rats.
Mol Cell Biochem.
1999;
202
131-140
19
Kordowiak A M, Trzos R, GrybosŽ R.
Insulin-like effects on liver Golgi membrane preparations of bis(oxalato)oxovanadate(IV) complex ion, a new vanadium compound.
Horm Metab Res.
1997;
29
104-108
20
Kordowiak A M, Dudek B, GrybosŽ R.
Influence of sodium(oxalato)oxovanadium(IV) on phospholipids in liver Golgi fractions from control and streptozotocin-diabetic rats.
Comp Biochem Physiol Part C.
2000;
125
11-16
21
Reul B A, Amin S S, Buchet J-P, Ongemba L N, Crans D C, Brichard S M.
Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats.
Brit J Pharmacol.
1999;
126
467-477
22
Kordowiak A, Turyna B, Kaczmarski F, Sarnecka-Keller M.
Comparison of rat plasma glycoprotein composition with biochemical activity and morphology of liver Golgi apparatus in streptozotocin-diabetes treated with insulin.
Folia Histochem Cytochem.
1981;
19
181-188
23
Kaczmarski F, Kordowiak A, Sarnecka-Keller M.
Influence of insulin on galactosyltransferase activity and morphology of the rat liver Golgi apparatus in control and streptozotocin-diabetic rats.
Path Res Pract.
1981;
172
130-137
24
Kordowiak A M.
Cytoprotective effect of 16,16’dimethylprostaglandin E2 (dmPGE2 ) on streptozotocin-induced biochemical alterations of Golgi-rich membrane fraction in comparison with morphology of rat liver Golgi apparatus in situ.
Path Res Pract.
1986;
181
397-402
25
Kordowiak A M, PolanŽski M, Da˛brosŽ W.
Influence of LEPK on biochemical activity and morphology in situ of liver Golgi apparatus from control and streptozotocin-diabetic rats.
Pol J Pathol.
1997;
48
87-93
26 Fleischer B. Isolation and characterisation of Golgi apparatus from rat liver. In: Fleischer S, Packer L (eds) Methods in Enzymology. New York; Acad Press Inc 1974 31A: 180-191
27
Lowry O H, Rosebrough N J, Farr A L, Randall R J.
Protein measurement with Folin phenol reagent.
J Biol Chem.
1951;
193
265-275
28 Somogyi M J, Nelson N. Determination of reducing sugars and carbohydrates. In: Whistler R, Wolprom R (eds) Methods in Carbohydrate Chemistry. New York, London; Acad Press Inc 1962 1: 380-394
29
Karnovsky M J.
A formaldehyde-glutaraldehyde fixative of high osmolarity for use in electron microscopy.
J Cell Biol.
1965;
27
137A-138A
30
Venable J H, Coggeshall R A.
Simplified lead citrate stain for use in electron microscopy.
J Cell Biol.
1965;
25
407- 408
31
Kurup S, Bhonde R R.
Combined effect of nicotinamide and streptozotocin on diabetic status in partially pancreatectomized adult BALB/c mice.
Horm Metab Res.
2000;
32
330-334
32
Z˙endzian-Piotrowska M, Bucki R, Górska M, Górski J.
Diabetes affects phospholipid content in the nuclei of the rat liver.
Horm Metab Res.
2000;
32
386-389
Dr. hab. Anna M. Kordowiak
Institute of Molecular Biology and Biotechnology, Jagiellonian University ·
Ul. Gronostajowa 7,30-387 · Cracow · Poland
Fax: + 48-12-252 6902